Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy

Thrombosis Research

Volumn 127, Issue 2, 2011, Pages 91-99

  Lip, Gregory Y H ^a   Rasmussen, Lars H ^b   Olsson, S Bertil ^c   Zetterstrand, Sofia ^d   Stahre, Christina ^d   Bylock, Anders ^d   Aunes Jansson, Maria ^d   Eriksson, Ulf ^d   Wåhlander, Karin ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Anticoagulation; Atrial fibrillation; AZD0837; Oral direct thrombin inhibitor; Vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; AZD 0837; CLOPIDOGREL; D DIMER; ECARIN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT DURATION; TREATMENT REFUSAL;

AGED; AGED, 80 AND OVER; AMIDINES; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; EMBOLISM; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

EID: 79151471916     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.11.012     Document Type: Article

References (27)

1. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen Riegel B ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Eur Heart J 27 16 2006 1979 2030
2. G.Y. Lip, and H.S. Lim Atrial fibrillation and stroke prevention Lancet Neurol 6 11 2007 981 993
3. National Collaborating Centre for Chronic Conditions Atrial fibrillation: national clinical guideline for management in primary and secondary care 2006 Royal College of Physicians London
4. Ansell J.; Hirsh J.; Poller L.; Bussey H.; Jacobson A.; and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl. 3 2004 204S 233S
5. J.S. Taggar, and G.Y. Lip Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range Curr Med Res Opin 24 5 2008 1455 1458
6. Singer D.E.; Albers G.W.; Dalen J.E.; Fang M.C.; Go A.S.; and Halperin J.L. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th ed. Chest 133 2008 Suppl. 6 546S 592S
7. S.J. Connolly, J. Pogue, J. Eikelboom, G. Flaker, P. Commerford, and M.G. Franzosi Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Circulation 118 20 2008 2029 2037
8. S.V. Morgan Between the Devil and the Deep Blue Sea-balancing the risks and potential benefits of warfarin for older people with atrial fibrillation Age Ageing 33 6 2004 544 547
9. H.D. White, M. Gruber, J. Feyzi, S. Kaatz, H.F. Tse, and S. Husted Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 3 2007 239 245
10. T.J. Bungard, W.A. Ghali, F.A. McAlister, A.M. Buchan, A.J. Cave, and P.G. Hamilton Physicians perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation Can Med Assoc J 165 3 2001 301 302
11. G.Y. Lip The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited Stroke 39 5 2008 1406 1408
12. J. Mant, F.D.R. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice, and G.Y.H. Lip Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 9586 2007 493 503
13. S. Connolly, J. Pogue, R. Hart, M. Pfeffer, S. Hohnloser, and S. Chrolavicius Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 9526 2006 1903 1912
14. S.J. Connolly, J. Pogue, S. Chrolavicius, R. Hart, M. Pfeffer, and S. Hohnloser Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 20 2009 2066 2078
15. Pehrsson S.; Johansson K.; Kjaer M.; and Elg M. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats Thromb and Haemost 104 2010 1242 1249
16. J. Deinum, C. Mattsson, T. Inghardt, and M. Elg Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637 Thromb Haemost 101 6 2009 1051 1059
17. Cullberg M.; Wåhlander K.; Jansson S.O.; Nystrom P.; Lonnerstedt C.; and Berggren A. Safety, pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor AZD0837 in young healthy volunteers Basic Clin Pharmacol Toxicol 101 Suppl. 1 2007 130 abstr 206
18. S.B. Olsson, L.H. Rasmussen, A. Tveit, E. Jensen, P. Wessman, and S. Paniflov Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation Thromb Haemost 103 2010 604 612
19. G.Y.H. Lip, L.H. Rasmussen, S.B. Olsson, E.C. Jensen, A.L. Persson, and U. Eriksson Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomised dose-guiding, safety and tolerability study of four doses of AZD0837 versus vitamin K antagonists Eur Heart J 30 2009 2897 2907
20. Hemker H.C.; Giesen P.; Al Dieri R.; Regnault V.; de Smedt E.; and Wagenvoord R. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma Pathophysiol Haemost Thromb 33 2003 4 15
21. G.Y. Lip, L. Frison, and M. Grind Effect of hypertension on anticoagulated patients with atrial fibrillation Eur Heart J 28 6 2007 752 759
22. M. Man-Son-Hing, G. Nichol, A. Lau, and A. Laupacis Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls Arch Intern Med 159 7 1999 677 685
23. P.J. Devereaux, D.R. Anderson, M.J. Gardner, W. Putnam, G.J. Flowerdew, and B.F. Brownell Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Br Med J 323 7323 2001 1218 1223
24. G.Y.H. Lip, S. Kamath, M. Jafri, A. Mohammed, and D. Bareford Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project Stroke 33 1 2002 238 242
25. G.Y.H. Lip, J. Zarifis, R.D. Watson, and D.G. Beevers Physician variation in the management of patients with atrial fibrillation Heart 75 2 1996 200 205
26. K.M. Schützer, M.K. Svensson, S. Zetterstrand, U.G. Eriksson, and K. Wåhlander Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837 Eur J Clin Pharmacol 66 2010 903 910
27. G.Y. Lip, P.L. Lip, J. Zarifis, R.D. Watson, D. Bareford, and G.D.O. Lowe Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin Circulation 94 3 1996 425 431